Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

9431 ARTÍCULOS , VIENDO DEL 3091 AL 3105

GCH-1 genetic variant may cause Parkinsonism by unmasking the subclinical nigral pathology

Shin JH, Lee WW, Lee JY, Kim HJ, Jeon B.

J Neurol. 2020 Jul;267(7):1952-1959. doi: 10.1007/s00415-020-09788-2. Epub 2020 Mar 13.

Parkinson's Disease in the Middle East, North Africa, and South Asia: Consensus from the International Parkinson and Movement Disorder Society Task Force for the Middle East

Khalil H, Chahine LM, Siddiqui J, Salari M, El-Jaafary S, Aldaajani Z, Abu Al-Melh M, Mohammad TM, Abu Snineh M, Syed NA, Bhatt M, Habib MA, Habahbeh M, Tabbal SD, Jeon B, Bajwa JA.

J Parkinsons Dis. 2020;10(2):729-741. doi: 10.3233/JPD-191751.

MRI of Motor and Nonmotor Therapy-Induced Complications in Parkinson's Disease

Donzuso G, Agosta F, Canu E, Filippi M.

Mov Disord. 2020 May;35(5):724-740. doi: 10.1002/mds.28025. Epub 2020 Mar 17.

Lipopolysaccharide animal models of Parkinson's disease: Recent progress and relevance to clinical disease

Deng I, Corrigan F, Zhai G, Zhou XF, Bobrovskaya L.

Brain Behav Immun Health. 2020 Mar 18;4:100060. doi: 10.1016/j.bbih.2020.100060. eCollection 2020 Apr.

Research advances on L-DOPA-induced dyskinesia: from animal models to human disease

Chen X, Wang Y, Wu H, Cheng C, Le W.

Neurol Sci. 2020 Aug;41(8):2055-2065. doi: 10.1007/s10072-020-04333-5. Epub 2020 Mar 17.

Telemedicine for Hyperkinetic Movement Disorders

Srinivasan R, Ben-Pazi H, Dekker M, Cubo E, Bloem B, Moukheiber E, Gonzalez-Santos J, Guttman M.

Tremor Other Hyperkinet Mov (N Y). 2020 Feb 17;10. doi: 10.7916/tohm.v0.698. eCollection 2020.

A Spanish Consensus on the Use of Safinamide for Parkinson's Disease in Clinical Practice

Pagonabarraga J, Arbelo JM, Grandas F, Luquin MR, Martínez Martín P, Rodríguez-Oroz MC, Valldeoriola F, Kulisevsky J.

Brain Sci. 2020 Mar 18;10(3):176. doi: 10.3390/brainsci10030176.

A Phase 2a Trial Investigating the Safety and Tolerability of the Novel Cortical Enhancer IRL752 in Parkinson's Disease Dementia

Svenningsson P, Odin P, Dizdar N, Johansson A, Grigoriou S, Tsitsi P, Wictorin K, Bergquist F, Nyholm D, Rinne J, Hansson F, Sonesson C, Tedroff J; IRL752 Collaborators.

Mov Disord. 2020 Jun;35(6):1046-1054. doi: 10.1002/mds.28020. Epub 2020 Mar 21.

[Psychosis and movement disorders in an adolescent with 22q11.2 deletion syndrome]

Zinkstok JR, Velders F, Rieken R, Houben M, Fiksinski A, van Amelsvoort TAMJ, Boot E.

Tijdschr Psychiatr. 2020;62(3):229-233.

Factor Analysis and Clustering of the Movement Disorder Society-Non-Motor Rating Scale

Martinez-Martin P, Rojo-Abuín JM, Weintraub D, Chaudhuri KR, Rodriguez-Blázquez C, Rizos A, Schrag A.

Mov Disord. 2020 Jun;35(6):969-975. doi: 10.1002/mds.28002. Epub 2020 Mar 27.

A Novel DBS Paradigm for Axial Features in Parkinson's Disease: A Randomized Crossover Study

Karl JA, Ouyang B, Goetz S, Metman LV.

Mov Disord. 2020 Aug;35(8):1369-1378. doi: 10.1002/mds.28048. Epub 2020 Apr 4.

Animal models for preclinical Parkinson's research: An update and critical appraisal

Cenci MA, Björklund A.

Prog Brain Res. 2020;252:27-59. doi: 10.1016/bs.pbr.2020.02.003. Epub 2020 Mar 21.

Once-Weekly Subcutaneous Delivery of Polymer-Linked Rotigotine (SER-214) Provides Continuous Plasma Levels in Parkinson's Disease Patients

Olanow CW, Standaert DG, Kieburtz K, Viegas TX, Moreadith R.

Mov Disord. 2020 Jun;35(6):1055-1061. doi: 10.1002/mds.28027. Epub 2020 Apr 6.

Historical Perspective: Models of Parkinson's Disease

Chia SJ, Tan EK, Chao YX.

Int J Mol Sci. 2020 Apr 2;21(7):2464. doi: 10.3390/ijms21072464.

Diphasic Worsening of Freezing of Gait in Parkinson's Disease

Perez Parra S, McKay JL, Factor SA.

Mov Disord Clin Pract. 2020 Mar 9;7(3):325-328. doi: 10.1002/mdc3.12918. eCollection 2020 Apr.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias